Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  TIPS - Trends in Pharmacological Sciences

• Publication date

  2009-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.tips.2009.09.006PMID 19837465PMCID PMC2787722
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative proteomic analysis of an Aspergillus fumigatus mutant deficient in glucosidase I (AfCwh41).

  2009cited by this paper
• Raltegravir: the first HIV type 1 integrase inhibitor.

  2009cited by this paper
• APOBEC3G-Depleted Resting CD4+ T Cells Remain Refractory to HIV1 Infection

  2009cited by this paper
• Likely Role of APOBEC3G-Mediated G-to-A Mutations in HIV-1 Evolution and Drug Resistance

  2009cited by this paper
• Structure, interaction and real‐time monitoring of the enzymatic reaction of wild‐type APOBEC3G

  2009cited by this paper
• Defining APOBEC3 Expression Patterns in Human Tissues and Hematopoietic Cell Subsets

  2009cited by this paper
• Cytoplasmic APOBEC3G Restricts Incoming Vif-Positive Human Immunodeficiency Virus Type 1 and Increases Two-Long Terminal Repeat Circle Formation in Activated T-Helper-Subtype Cells

  2009cited by this paper
• An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model.

  2009cited by this paper
• APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA

  2009cited by this paper
• Reassessing the Role of APOBEC3G in Human Immunodeficiency Virus Type 1 Infection of Quiescent CD4+ T-Cells

  2009cited by this paper
• A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors

  2009cited by this paper
• Analysis of the Percentage of Human Immunodeficiency Virus Type 1 Sequences That Are Hypermutated and Markers of Disease Progression in a Longitudinal Cohort, Including One Individual with a Partially Defective Vif

  2009cited by this paper
• The C-terminal domain of the HIV-1 Vif protein is natively unfolded in its unbound state.

  2009cited by this paper
• Identification of a Novel WxSLVK Motif in the N Terminus of Human Immunodeficiency Virus and Simian Immunodeficiency Virus Vif That Is Critical for APOBEC3G and APOBEC3F Neutralization

  2009cited by this paper
• Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA

  2009cited by this paper
• A Patch of Positively Charged Amino Acids Surrounding the Human Immunodeficiency Virus Type 1 Vif SLVx4Yx9Y Motif Influences Its Interaction with APOBEC3G

  2009cited by this paper
• Functional domain organization of human APOBEC3G.

  2008cited by this paper
• Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation.

  2008cited by this paper
• Structural Insight into the Human Immunodeficiency Virus Vif SOCS Box and Its Role in Human E3 Ubiquitin Ligase Assembly

  2008cited by this paper
• Regulation of APOBEC3 Proteins by a Novel YXXL Motif in Human Immunodeficiency Virus Type 1 Vif and Simian Immunodeficiency Virus SIVagm Vif

  2008cited by this paper
• Small-molecule inhibition of HIV-1 Vif

  2008cited by this paper
• The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation.

  2008cited by this paper
• Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G

  2008cited by this paper
• Challenges in the development of an HIV-1 vaccine

  2008cited by this paper
• Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu

  2008cited by this paper
• Maraviroc: The First of a New Class of Antiretroviral Agents

  2008cited by this paper
• Failure of the Merck HIV vaccine: an uncertain step forward.

  2008cited by this paper
• Cytidine deamination induced HIV-1 drug resistance

  2008cited by this paper
• Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G.

  2008cited by this paper
• Distinct Determinants in HIV-1 Vif and Human APOBEC3 Proteins Are Required for the Suppression of Diverse Host Anti-Viral Proteins

  2008cited by this paper
• Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications

  2008cited by this paper
• Distinct Domains within APOBEC3G and APOBEC3F Interact with Separate Regions of Human Immunodeficiency Virus Type 1 Vif

  2008cited by this paper
• Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.

  2008cited by this paper
• APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells.

  2008cited by this paper
• The DNA Deaminase Activity of Human APOBEC3G Is Required for Ty1, MusD, and Human Immunodeficiency Virus Type 1 Restriction

  2008cited by this paper
• Fluorescence Quenching of CdTe Nanocrystals by Bound Gold Nanoparticles in Aqueous Solution

  2008cited by this paper
• Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F.

  2008cited by this paper
• The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.

  2008cited by this paper
• Human APOBEC3G Can Restrict Retroviral Infection in Avian Cells and Acts Independently of both UNG and SMUG1

  2008cited by this paper
• APOBEC3G Inhibits Elongation of HIV-1 Reverse Transcripts

  2008cited by this paper
• Human Immunodeficiency Virus (HIV) Type 1 Proviral Hypermutation Correlates with CD4 Count in HIV-Infected Women from Kenya

  2008cited by this paper
• Identification of Amino Acid Residues in APOBEC3G Required for Regulation by Human Immunodeficiency Virus Type 1 Vif and Virion Encapsidation

  2007cited by this paper
• Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.

  2007cited by this paper
• APOBEC3G Inhibits DNA Strand Transfer during HIV-1 Reverse Transcription*

  2007cited by this paper
• Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.

  2007cited by this paper
• Mass spectrometry analysis of HIV‐1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity

  2007cited by this paper
• Cytidine Deaminases APOBEC3G and APOBEC3F Interact with Human Immunodeficiency Virus Type 1 Integrase and Inhibit Proviral DNA Formation

  2007cited by this paper
• Human Immunodeficiency Virus Type 1 cDNAs Produced in the Presence of APOBEC3G Exhibit Defects in Plus-Strand DNA Transfer and Integration

  2007cited by this paper
• Role of APOBEC3G/F-Mediated Hypermutation in the Control of Human Immunodeficiency Virus Type 1 in Elite Suppressors

  2007cited by this paper
• A potent and orally active HIV-1 integrase inhibitor.

  2007cited by this paper
• APOBEC3F Can Inhibit the Accumulation of HIV-1 Reverse Transcription Products in the Absence of Hypermutation

  2007cited by this paper
• The Interaction of APOBEC3G with Human Immunodeficiency Virus Type 1 Nucleocapsid Inhibits tRNA3Lys Annealing to Viral RNA

  2007cited by this paper
• Virion-associated Uracil DNA Glycosylase-2 and Apurinic/Apyrimidinic Endonuclease Are Involved in the Degradation of APOBEC3G-edited Nascent HIV-1 DNA*

  2007cited by this paper
• Identification of an APOBEC3G Binding Site in Human Immunodeficiency Virus Type 1 Vif and Inhibitors of Vif-APOBEC3G Binding

  2007cited by this paper
• Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G

  2007cited by this paper
• Identification of Two Distinct Human Immunodeficiency Virus Type 1 Vif Determinants Critical for Interactions with Human APOBEC3G and APOBEC3F

  2007cited by this paper
• Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G

  2007cited by this paper
• Enzymatically Active APOBEC3G Is Required for Efficient Inhibition of Human Immunodeficiency Virus Type 1

  2007cited by this paper
• Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F.

  2007cited by this paper
• Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression.

  2007cited by this paper
• Alpha Interferon Potently Enhances the Anti-Human Immunodeficiency Virus Type 1 Activity of APOBEC3G in Resting Primary CD4 T Cells

  2006cited by this paper
• Distinct Patterns of Cytokine Regulation of APOBEC3G Expression and Activity in Primary Lymphocytes, Macrophages, and Dendritic Cells*

  2006cited by this paper
• Mutational Alteration of Human Immunodeficiency Virus Type 1 Vif Allows for Functional Interaction with Nonhuman Primate APOBEC3G

  2006cited by this paper
• Differential Requirement for Conserved Tryptophans in Human Immunodeficiency Virus Type 1 Vif for the Selective Suppression of APOBEC3G and APOBEC3F

  2006cited by this paper
• Biochemical Activities of Highly Purified, Catalytically Active Human APOBEC3G: Correlation with Antiviral Effect

  2006cited by this paper
• Inhibition of \batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \(\mathrm{tRNA}_{3}^{\mathrm{Lys}}\) \end{document}-Primed Reverse Transcription by Human APOBEC3G during Human Immunodeficiency

  2006cited by this paper
• Identification of APOBEC3DE as Another Antiretroviral Factor from the Human APOBEC Family

  2006cited by this paper
• High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition

  2006cited by this paper
• A Zinc-binding Region in Vif Binds Cul5 and Determines Cullin Selection*

  2006cited by this paper
• Uracil DNA Glycosylase Is Dispensable for Human Immunodeficiency Virus Type 1 Replication and Does Not Contribute to the Antiviral Effects of the Cytidine Deaminase Apobec3G

  2006cited by this paper
• Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins.

  2005cited by this paper
• Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification

  2005cited by this paper
• High-Throughput Human Immunodeficiency Virus Type 1 (HIV-1) Full Replication Assay That Includes HIV-1 Vif as an Antiviral Target

  2005cited by this paper
• Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases.

  2005cited by this paper
• Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.

  2005cited by this paper
• Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities

  2005cited by this paper
• Beyond Efficacy: The Impact of Combination Antiretroviral Therapy on Quality of Life

  2005cited by this paper
• Mice Deficient in APOBEC2 and APOBEC3

  2005cited by this paper
• Small-Molecule Inhibition of TNF-α

  2005cited by this paper
• Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G.

  2005cited by this paper
• The Retroviral Hypermutation Specificity of APOBEC3F and APOBEC3G Is Governed by the C-terminal DNA Cytosine Deaminase Domain*

  2005cited by this paper
• Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells

  2005cited by this paper
• Complementary function of the two catalytic domains of APOBEC3G.

  2005cited by this paper
• G→A Hypermutation in Protease and Reverse Transcriptase Regions of Human Immunodeficiency Virus Type 1 Residing in Resting CD4+ T Cells In Vivo

  2005cited by this paper
• Regulation of Apobec3F and Human Immunodeficiency Virus Type 1 Vif by Vif-Cul5-ElonB/C E3 Ubiquitin Ligase

  2005cited by this paper
• A Single Amino Acid Determinant Governs the Species-specific Sensitivity of APOBEC3G to Vif Action*

  2004cited by this paper
• A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV‐1 and HIV‐2 Vif proteins

  2004cited by this paper
• The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys

  2004cited by this paper
• Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1

  2004cited by this paper
• A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.

  2004cited by this paper
• A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).

  2004cited by this paper
• APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.

  2004cited by this paper
• Vif Overcomes the Innate Antiviral Activity of APOBEC3G by Promoting Its Degradation in the Ubiquitin-Proteasome Pathway*

  2004cited by this paper
• Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome

  2004cited by this paper
• Functional domains of APOBEC3G required for antiviral activity

  2004cited by this paper
• A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor.

  2004cited by this paper
• Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.

  2004cited by this paper
• Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines.

  2004cited by this paper
• Human Apolipoprotein B mRNA-editing Enzyme-catalytic Polypeptide-like 3G (APOBEC3G) Is Incorporated into HIV-1 Virions through Interactions with Viral and Nonviral RNAs*

  2004cited by this paper
• APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase.

  2004cited by this paper

• Potent dual block to HIV-1 infection using lentiviral vectors expressing fusion inhibitor peptide mC46- and Vif-resistant APOBEC3G

  2023cites this paper
• Mutagenic Activity of AID/APOBEC Deaminases in Antiviral Defense and Carcinogenesis

  2022cites this paper
• Impact of Human Leukocyte Antigen-Associated Polymorphisms on Variability of HIV-1 Accessory and Regulatory Proteins

  2021cites this paper
• Development of Lentiviral Vectors for HIV-1 Gene Therapy with Vif-Resistant APOBEC3G

  2019cites this paper
• Vesiculovirus G protein-based stable cell lines for continuous lentiviral vector production

  2018cites this paper
• Viral subversion of APOBEC3s: Lessons for anti-tumor immunity and tumor immunotherapy

  2018cites this paper
• Novel host restriction factors implicated in HIV-1 replication.

  2018cites this paper
• Fab-based inhibitors reveal ubiquitin independent functions for HIV Vif neutralization of APOBEC3 restriction factors

  2018cites this paper
• APOBEC Enzymes as Targets for Virus and Cancer Therapy.

  2017cites this paper
• Development of an Assay to study the Kinetics of HIV-1 Capsid Uncoating

  2017cites this paper
• An in silico approach for identification of novel inhibitors as a potential therapeutics targeting HIV-1 viral infectivity factor.

  2015cites this paper
• Retroviral factors promoting infectivity.

  2015cites this paper
• Redoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1.

  2015cites this paper
• Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.

  2014cites this paper
• An amorphous silicon photodiode microfluidic chip to detect nanomolar quantities of HIV-1 virion infectivity factor.

  2014cites this paper
• Requirement of HIV-1 Vif C-terminus for Vif-CBF-β interaction and assembly of CUL5-containing E3 ligase

  2014cites this paper
• USE OF GENE THERAPY TO CURE AIDS

  2014cites this paper
• Problems and Prospects of Gene Therapy Against HIV

  2014cites this paper
• CBFβ stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression.

  2013cites this paper
• Nuclear import of APOBEC3F-labeled HIV-1 preintegration complexes

  2013cites this paper
• Mapping the Vif-A3G interaction using peptide arrays: a basis for anti-HIV lead peptides.

  2013cites this paper
• Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F

  2013cites this paper
• Combinatorial RNA-based gene therapy for the treatment of HIV/AIDS

  2013cites this paper
• Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F.

  2013cites this paper
• Structure-activity relationships and design of viral mutagens and application to lethal mutagenesis.

  2013cites this paper
• Role of HIV-1 Vif in viral replication : translational regulation of APOBEC3G and RNA chaperone activity

  2013cites this paper
• Small‐Molecule APOBEC3G DNA Cytosine Deaminase Inhibitors Based on a 4‐Amino‐1,2,4‐triazole‐3‐thiol Scaffold

  2013cites this paper
• Impact of H216 on the DNA Binding and Catalytic Activities of the HIV Restriction Factor APOBEC3G

  2013cites this paper
• A Comparison of Two Single-Stranded DNA Binding Models by Mutational Analysis of APOBEC3G

  2012cites this paper
• APOBEC3G Restricts HIV-1 to a Greater Extent than APOBEC3F and APOBEC3DE in Human Primary CD4+ T Cells and Macrophages

  2012cites this paper
• Inhibition of a NEDD8 Cascade Restores Restriction of HIV by APOBEC3G

  2012cites this paper
• First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G.

  2012cites this paper
• The role of Vif oligomerization and RNA chaperone activity in HIV-1 replication.

  2012cites this paper
• Comparative Analysis of Synaptic Vesicles Present in the Axon 13 of Hippocampal Neurons in Wild-Type and Synapsin Triple Knock-Out Mice

  2012cites this paper
• APOBEC 3 G Restricts HIV-1 to a Greater Extent than APOBEC 3 F and APOBEC 3 DE in Human Primary CD 4 T Cells and Macrophages

  2012cites this paper
• Recombinant origin, contamination, and de-discovery of XMRV.

  2012cites this paper
• Structural Studies of the Anti-HIV Human Protein APOBEC3G Catalytic Domain: A Dissertation

  2011cites this paper
• The Role of Amino-Terminal Sequences in Cellular Localization and Antiviral Activity of APOBEC3B

  2011cites this paper
• Analysis of Human APOBEC3H Haplotypes and Anti-Human Immunodeficiency Virus Type 1 Activity

  2011cites this paper
• Ex vivo gene therapy for HIV-1 treatment.

  2011cites this paper
• The Activity Spectrum of Vif from Multiple HIV-1 Subtypes against APOBEC3G, APOBEC3F, and APOBEC3H

  2011cites this paper
• Development of a high throughput cell-based assay to screen for inhibitors of HIV-1 Vpr oligomerization

  2011cites this paper
• Identification of a Critical T(Q/D/E)x5ADx2(I/L) Motif from Primate Lentivirus Vif Proteins That Regulate APOBEC3G and APOBEC3F Neutralizing Activity

  2010cites this paper
• Moderate Influence of Human APOBEC3F on HIV-1 Replication in Primary Lymphocytes

  2010influential citation
• Identification of Specific Determinants of Human APOBEC3F, APOBEC3C, and APOBEC3DE and African Green Monkey APOBEC3F That Interact with HIV-1 Vif

  2010cites this paper
• Identification of a Critical T(Q/D/E)x 5 ADx 2 (I/L) Motif from Primate Lentivirus Vif Proteins That Regulate APOBEC3G and APOBEC3F Neutralizing Activity (cid:1)

  2010cites this paper
• Innate immunity in resistance to HIV infection.

  2010cites this paper
• Long-Term Restriction by APOBEC3F Selects Human Immunodeficiency Virus Type 1 Variants with Restored Vif Function

  2010cites this paper
• Lentiviral Vif Degrades the APOBEC3Z3/APOBEC3H Protein of Its Mammalian Host and Is Capable of Cross-Species Activity

  2010cites this paper
• Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics

  2010cites this paper
• APOBEC3F and APOBEC3G Inhibit HIV-1 DNA Integration by Different Mechanisms (cid:1)

  2010cites this paper
• Structural Model for Deoxycytidine Deamination Mechanisms of the HIV-1 Inactivation Enzyme APOBEC3G*♦

  2010cites this paper
• Identification of 81LGxGxxIxW89 and 171EDRW174 Domains from Human Immunodeficiency Virus Type 1 Vif That Regulate APOBEC3G and APOBEC3F Neutralizing Activity

  2010cites this paper
• Dynamics of the Mammalian APOBEC3 Locus and the Relationship Between Mammalian APOBEC3 and Lentiviral Vif Proteins

  2010cites this paper
• APOBEC3F and APOBEC3G Inhibit HIV-1 DNA Integration by Different Mechanisms

  2010cites this paper